November 05, 2020
1 min read
Save
STAAR begins commercialization of EVO Viva lens in Europe
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Initial commercialization of the EVO Viva lens, including the first patient implant, has begun, STAAR Surgical announced in a press release.
“Our presbyopia-correcting EVO Viva lens is aimed at patients in their 40s and 50s who struggle with near vision and the burdens associated with wearing reading glasses,” Caren Mason, president and CEO of STAAR Surgical, said in the release.
Consumer websites are available in French, Dutch and Spanish, with more local language websites forthcoming, the release said.
The EVO and EVO Viva versions of the ICL are not approved for sale in the United States.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.